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S60Objective: The Endovascular Valve Edge-to-Edge Repair Study (EVEREST II) is a prospective, multicenter,
randomized controlled trial comparing percutaneous repair with the MitraClip device to mitral valve (MV) sur-
gery in the treatment of mitral regurgitation. The present study analyzed the patient characteristics and treatment
effects on mitral repair versus replacement.
Methods:Of 279 patients enrolled, 80 surgical patients underwent 82 MVoperations and 178 underwent an ini-
tial MitraClip procedure, of whom 37 underwent a subsequent MV operation within 1 year of their index the
MitraClip procedure. A logistic regression model was used to predict MV replacement according to valve pa-
thology, etiology of mitral regurgitation, age, previous cardiac surgery, and treatment group.
Results: The rate of percutaneous or surgical MV repair at 1 year was 89% (158/178) in patients initially re-
ceiving the MitraClip device versus 84% (67/80) in the surgical patients (P ¼ .36). Surgical repair was per-
formed after the MitraClip procedure in 20 (54%) of 37patients (P<.001 vs surgery). In both the MitraClip
device and surgery groups, MV replacement was significantly associated with anterior leaflet pathology (P ¼
.035). Logistic regression analysis showed that anterior leaflet pathology predicted MV replacement. In 5
(13.5%) of 37 patients undergoing surgery after MitraClip therapy, replacement was performed in part because
of MV injury associated with the MitraClip procedure.
Conclusions: These data suggest that anterior leaflet pathology is strongly associated with MV replacement in
patients undergoing either de novoMV surgery or surgery afterMitraClip therapy.MitraClip therapy has a repair
rate similar to surgery through 1 year but also imparts a risk of replacement of a potentially repairable valve.
(J Thorac Cardiovasc Surg 2012;143:S60-3)In patients undergoing surgery for mitral regurgitation
(MR), mitral repair has advantages over mitral replacement
of improved durability, less anticoagulation, and better pres-
ervation of left ventricular function.1 As mitral repair tech-
niques have improved, some investigators have concluded
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The Journal of Thoracic and Cardiovascular Surgdegenerative disease can and should be repaired.2 However,
large population-based samples have shownMV repair rates
of only 50%.3 Factors proposed to predict MV replacement
instead of repair include surgeon factors,3,4 older patient
age,4 anterior or bileaflet mitral pathology,4 previous medi-
astinal radiotherapy,5 calcification,4 previous cardiac sur-
gery, and functional etiology of MR.6 Most of these
studies are potentially subject to patient selection bias and
problems from retrospective data analysis.
The Endovascular Valve Edge-to-Edge Repair Study
(EVEREST II) is a prospective, multicenter, randomized
controlled trial comparing the MitraClip system with MV
surgery in the treatment of MR.7,8 Data from the
EVEREST II trial were analyzed to meet 4 objectives:
1. To determine whether the overall repair rate is compara-
ble between patients who underwent the MitraClip pro-
cedure versus de novo surgery.
2. To determine the specific baseline demographic or valve
characteristics that are predictive of MV replacement.
3. To assess the MitraClip procedure effect on the ability to
surgically repair the valve.
4. To evaluate the effect of surgeon experience on MV
replacement.ery c April 2012
Glower et al Technical ConsiderationsAbbreviations and Acronyms
EVEREST II ¼ Endovascular Valve
Edge-to-Edge Repair Study
MV ¼ mitral valve
MR ¼ mitral regurgitationMETHODS
After individual institutional review board approval, 279 patients were
enrolled at 37 sites in North America and randomized 2:1 (184 to the
MitraClip device and 95 to surgery) in the EVEREST II randomized con-
trolled trial.9 Patients with functional MR or degenerative MR involving
anterior, posterior, or bileaflet disease were eligible for enrollment, and re-
pair and replacement surgery were considered acceptable outcomes of the
trial in the surgery group. Before randomization, the surgeons were asked
to indicate whether surgical MV repair versus replacement was planned.
A comparison of the overall repair rate between the patients who under-
went the MitraClip procedure versus de novo surgery was performed using
Fisher’s exact test.
Specific baseline demographic or valve characteristics were assessed for
association with MV repair versus replacement on univariate analyses and
in a multivariate logistic regression model, including the following vari-
ables: anterior or bileaflet leaflet pathology, functional etiology ofMR, pre-
vious cardiac surgery, patient age, and treatment group (MitraClip vs
surgery). Three MitraClip patients who were not implanted with a Mitra-
Clip device and did not undergo subsequent MV surgery were excluded
from the present analysis because they received no treatment (repair or re-
placement) for MR.
MV injury or difficulty removing the MitraClip device was assessed by
retrospectively reviewing the operative notes. To assess surgeon experi-
ence, surgeons were asked to provide the number of MV repairs and re-
placements performed in the year before enrolling patients in the
EVEREST II randomized controlled trial.
The baseline characteristics between 2 groups were compared using
Fisher’s exact test for categorical variables and Student t test for continuous
variables.
RESULTS
Surgical Results Through 1 Year in MitraClip and
Surgery Groups
Of the 279 patients, 178 were randomized and treated in
the MitraClip group, and 80 were randomized to the surgery
group. The planned surgical repair rate before randomiza-
tion was 92% for treated patients in both the MitraClip
and surgery groups. Through 1 year, 37 (21%) of 178 Mi-
traClip patients underwent subsequent MV surgery, of
whom 20 (54%) underwent MV repair. The planned repair
rate for the 37 patients who underwent surgery after the Mi-
traClip procedure (92%) was significantly greater than the
actual repair rate (54%, P ¼ .005). The number of Mitra-
Clip devices implanted (17 with no clip, 7 with 1 clip,
and 13 with 2 clips) was not associated with MV replace-
ment (P ¼ .12). The median interval to MV surgery after
the MitraClip procedure for these 37 patients was 41
days, with 28 (76%) of 37 performed within 90 days
from the index procedure. As previously reported byThe Journal of Thoracic and CarFeldman and colleagues,7 the reason for surgery in these
37 patients was no MitraClip device implanted in 17, MR
grade 3þor 4þafter MitraClip implantation before hospital
discharge in 5, MR grade 3þor 4þafter single leaflet device
attachment in 9, and MR grade 3þor 4þafter MitraClip im-
plantation after hospital discharge despite dual leaflet at-
tachment in 3 and symptoms in 3.
In the de novo surgery group, 67 (84%) of 80 patients un-
derwent MV repair surgery (P<.001 vs surgery after Mitra-
Clip) through 1 year. In this group, the planned surgical
repair rate was 92% (P ¼ .14, 84% [67/80] vs 92%
[60/67]). Two surgery patients underwent MV replacement
as a second operation after the initial repair (Figure 1).Overall Repair (Percutaneous and Surgical) and
Replacement Rates Through 1 Year
Among the 178 patients who underwent the MitraClip
procedure in the MitraClip group, 158 (89%) underwent re-
pair, either percutaneous (n¼ 138) or surgery (n¼ 20) after
the MitraClip procedure, and was not significantly different
from the repair rate in the surgery group (67/80 [84%],
P ¼ .36) through 1 year.Predictors of MV Repair Versus Replacement
The baseline characteristics of the MitraClip (n ¼ 178)
and surgery (n ¼ 80) groups, including age, functional eti-
ology of MR, previous cardiac surgery, and anterior ante-
rior/bileaflet pathology were not significantly different
(P ¼ .47). When all patients were combined (percutaneous
and surgical), the only variable that showed a trend toward
a difference between groups was anterior/bileaflet pathol-
ogy on univariate analysis, with the patients undergoing re-
placement showing a trend toward a greater incidence of
anterior/bileaflet pathology (47% vs 28%, P ¼ .055).
Age, functional etiology of MR, previous cardiac sur-
gery, incidence of anterior/bileaflet pathology), and treat-
ment group (MitraClip device vs surgery) were included
in a logistic regression model to determine whether any of
these variables was associated with MV replacement. Ante-
rior/bileaflet pathology was the only variable significantly
associated with MV replacement (P ¼ .037). In the present
small sample size, the association between MitraClip treat-
ment and MV replacement was not significant (P ¼ .086).Effect of MitraClip Procedure on Ability to
Surgically Repair the Valve
Of the 37 patients who underwent surgery after theMitra-
Clip procedure, 15 (41%) underwent replacement when re-
pair was planned before randomization, 19 (51%)
underwent repair as planned preprocedurally, 2 (5%) under-
went replacement as planned preprocedurally, and the re-
maining patient (3%) underwent MV repair when
replacement was planned (n ¼ 1).diovascular Surgery c Volume 143, Number 4S S61
FIGURE 1. Type of procedure (percutaneous or surgical) performed through 1 year for MitraClip and surgery groups.
Technical Considerations Glower et alOf the 37 cases of MV surgery after the MitraClip proce-
dure, valve injury was reported by the surgeon in 11 (30%);
6 cases were reported to be related to the MitraClip proce-
dure and the remaining 5 were reported to be related to dif-
ficulty in removing the device during explantation. In 6 of
the 11 cases in which MV injury was reported, MV repair
was able to be performed as planned; however, in the re-
maining 5 cases, the surgeon chose to replace the valve
(5/37 [13.5%]). Of these 5 patients, 4 had previously
been implanted with 2MitraClip devices, and the remaining
patient was not implanted with aMitraClip device. Replace-
ment was performed 6, 33, 41, 52, and 54 days after the Mi-
traClip procedure. The surgical repair rate in patients noted
to have MV injury was not different from the remaining pa-
tients undergoing surgery after the MitraClip device (6/11
[54%] vs 15/26 [58%], P ¼ .89). To compare the effect
of the interval to surgery after the MitraClip procedure on
the surgical mitral repair rate, the repair rate of MitraClip
patients undergoing surgery after 90 days (4/10 [40%])
was compared with the repair rate in patients undergoing
surgery within 90 days (13/27 [48%], P ¼ .95).
Of the 80 patients in the surgery group, 8 (10%) under-
went replacement when repair was planned preprocedurally,
67 (84%) underwent repair as planned preprocedurally, and
5 (6%) underwent replacement as planned preprocedurally.
For those 8 de novo surgery patients who underwent un-
planned replacement, the reasons for the replacement were
recurrent MR requiring repeat operation in 2, attempted
repair but residual MR present intraprocedurally in 4,
advanced age in 1, and bileaflet disease with myxomatous
leaflets in 1.S62 The Journal of Thoracic and Cardiovascular SurgEffect of Surgeon Experience on MV Replacement
In centers in which patients underwent MV surgery after
the MitraClip procedure (n ¼ 37), the surgeon had per-
formed a mean of 62 MV surgeries (40 repairs and 22 re-
placements; median, 52 in the year before participation in
EVEREST II). An average of 60 MV surgeries (38 repairs
and 22 replacements; median, 52) were performed in cen-
ters in which MitraClip patients underwent MV repair
(n ¼ 20). An average of 64 MV surgeries (41 repairs and
23 replacements; median, 52) were performed in the centers
in which 17MitraClip patients underwent MV replacement.
In the centers for the surgery group, the mean number of
MV surgeries performed in the year before EVEREST II
was 60 (39 repairs and 21 replacements; median, 45) in
the 67 de novo surgery patients who underwent MV repair.
It was 61 (39 repairs and 22 replacements; median, 46) in
the 13 de novo surgery patients who underwent MV re-
placement. On examining the de novo surgery and surgery
after the MitraClip patients combined, no difference was
found in surgeon experience (P ¼ .87) when all patients
who underwent MV repair (n ¼ 87) were compared with
those patients who underwent MV replacement (n ¼ 30).
CONCLUSIONS
The EVEREST II trail provides unique data for patients
with surgical MR owing to prospective data collection
and central echocardiographic core laboratory analysis.
The EVEREST II data confirm previously reported that an-
terior and bileaflet prolapse are associated with replacement
versus repair. Patient age, functional etiology of MR, previ-
ous cardiac surgery, surgeon experience, and interval fromery c April 2012
Glower et al Technical ConsiderationsMitraClip procedure could not be confirmed as risk factors
for replacement in the present series. These data also show
that the 1-year mitral repair rate after initial MitraClip treat-
ment was similar to that of de novo surgery (158/178 [89%]
vs 67/80 [84%]).
However, the multivariate analysis and intraoperative
findings suggest some increased likelihood of ultimate
MV replacement associated with MitraClip therapy. The
lower surgical repair rate after MitraClip placement versus
de novo surgery (20/37 [54%] vs 67/80 [84%]) resulted in
part from valves failing after the MitraClip procedure had
a greater prevalence of anterior/bileaflet pathology. How-
ever, in 5 (14%) of the 37 patients undergoing surgery after
MitraClip, replacement occurred after MVinjury associated
with the MitraClip procedure or device explantation.
Although the likelihood of undergoing MV replacement
instead of repair because of MitraClip therapy was not high
(5/178 [3%]), some caution is warranted in patient selection
for MitraClip therapy. Furthermore, because all patients
with unsuccessful initial repairs (either by MitraClip or sur-
gery) did not ultimately return for surgery, it is impossible to
know how many more unplanned replacements might have
occurred in this cohort if a subsequent operation were per-
formed. Rogers and colleagues9 reported successful MV re-
pair up to 5 years after MitraClip placement, and the 5
patients requiring unanticipated mitral replacement after
MitraClip therapy all underwent surgery fewer than 60
days after MitraClip placement.
Surgical extraction of the MitraClip from a mitral leaflet
can be as simple as lifting the MitraClip device from the
leaflets early after MitraClip placement. However, after
30 days after MitraClip placement, the MitraClip device
will have some degree of surrounding fibrosis that might
need surgical debridement, along with opening the arms
of theMitraClip device to facilitate explantation.10 Explant-
ing the MitraClip device from the leaflets is facilitated by
pulling the central lock harness of the MitraClip, thereby
opening the grippers and arms of theMitraClip device.10 In-
creased surgical experience with MitraClip removal tech-
niques will likely improve the ease of mitral repair after
MitraClip placement.The Journal of Thoracic and CarThe EVEREST II data offer important insight into patient
selection for MitraClip therapy. The potential for MitraClip
therapy to reduce the likelihood of surgical repair would be
of little concern to patients who have no surgical options or
who have a greater risk of surgical mortality or who have
limited life expectancy. Patients who are surgical candi-
dates with a high probability of surgical repair will have
to weigh the safety advantages of percutaneous MitraClip
therapy against the possibility of ultimately needing mitral
replacement instead of repair because of previousMitraClip
placement.
In conclusion, using these data from the EVEREST II
trial, selected patients who have high operative risk of sur-
gical mitral repair might be the most appropriate candidates
for MitraClip therapy at this early stage in the development
of this novel technology. Additional follow-up will eluci-
date the long-term effects of MitraClip placement on mitral
reparability.
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